We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+33.99%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.2B
AUM Growth
+$88.2M
Cap. Flow
-$49.3M
Cap. Flow %
-4.12%
Top 10 Hldgs %
81.29%
Holding
35
New
8
Increased
4
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$51.9M
2
SAGE
Sage Therapeutics
SAGE
+$44.1M
3
SCPH
scPharmaceuticals
SCPH
+$40.3M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$18.7M
5
ECYT
Endocyte, Inc. Common Stock
ECYT
+$16M

Top Sells

Rank Stock Value
1
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$54.3M
2
RXDX
Ignyta, Inc.
RXDX
+$50.7M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$47.4M
4
INSM icon
Insmed
INSM
+$22.6M
5
ACOR
Acorda Therapeutics
ACOR
+$21.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHMA
26
DELISTED
Chiasma, Inc. Common Stock
CHMA
$2M 0.17%
1,176,806
-219,594
-16% -$461K
ACHN
27
DELISTED
Achillion Pharmaceuticals
ACHN
$1.69M 0.14%
585,890
-13,047,330
-96% -$47.4M
INSM icon
28
Insmed
INSM
$22.4B
– –
-722,714
Closed -$22.6M
SGMO
29
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-1,250,000
Closed -$18.8M
TGTX icon
30
TG Therapeutics
TGTX
$8.19B
– –
-700,000
Closed -$8.29M
VNDA icon
31
Vanda Pharmaceuticals
VNDA
$304M
– –
-243,971
Closed -$4.37M
ACOR
32
DELISTED
Acorda Therapeutics
ACOR
– –
-7,502
Closed -$21.3M
IMMU
33
DELISTED
Immunomedics Inc
IMMU
– –
-1,478,742
Closed -$20.7M
RXDX
34
DELISTED
Ignyta, Inc.
RXDX
– –
-4,106,601
Closed -$50.7M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, RA Capital Management held 35 positions worth $1.2B, up 8% from $1.11B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

RA Capital Management withdrew a net $49.3M in Q4 2017, closing 8 positions and reducing 6 holdings. Its most notable exit was Ignyta, Inc., an estimated $50.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier.

Against the trend, RA Capital Management opened a new position in InflaRx worth $60.3M.

  • RA Capital Management's largest Q4 2017 buy was InflaRx: 2,876,080 shares worth $60.3M.
  • RA Capital Management added most to Dicerna Pharmaceuticals, Inc. in Q4 2017, an estimated $18.7M increase.
  • RA Capital Management's biggest Q4 2017 reduction was G1 Therapeutics, Inc. Common Stock, cutting an estimated $54.3M.
  • RA Capital Management fully exited Ignyta, Inc. in Q4 2017, selling an estimated $50.7M.
  • RA Capital Management's ten largest holdings make up 81% of its $1.2B portfolio in Q4 2017.
  • RA Capital Management opened 8 new positions and closed 8 in Q4 2017.
  • RA Capital Management's portfolio value rose 8% quarter-over-quarter to $1.2B.

Based on RA Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.